The ProScan test is based on key peer-reviewed studies that identified several genetic tumor markers that enable a more precise stratification of the risk profile of cancer patients.
The ProScan test comprises probes for specific genomic loci of which copy number gains and losses have been shown to correlate with risk of recurrence and metastasis in patients post-prostatectomy.
According to the company, these additional probes are a further enhancement of the CMDX solid tumor array platform design which enables whole-genome tumor profiling, or genomic grading, while also providing information about the copy-number status of specific disease-associated loci.
Amit Kumar, president and CEO of CombiMatrix, said: “The launch of the ProScan test further solidifies our leadership position in the array-based genetic testing market, in which we provide by far the broadest portfolio of tests. We’re pleased to make this cancer diagnostic test available to physicians and to deliver on our commitment to launch the ProScan test by the end of 2008.”